Eisai begins Phase III CLEAR Study of lenvatinib as first-line therapy for RCC

Japanese-based pharmaceutical company Eisai has commenced its Phase III CLEAR Study of Lenvima (lenvatinib) combined with Keytruda (pembrolizumab) and Lenvima with everolimus against sunitinib to treat advanced renal cell carcinoma (RCC) in the first …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news